Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Colorectal Neoplasms 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Breast Neoplasms 1

Interventions

ruxolitinib 7givinostat hydrochloride 3givinostat 3anagrelide 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3bomedemstat 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2LY2784544 2spartalizumab 1sonidegib 1sabatolimab 1navitoclax 1lestaurtinib 1imetelstat 1ON 01910 1NIS-793 1N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide 1INCB057643 1Fentanyl 1Diagnosis 1Decitabine 1Celecoxib 1CPI-0610 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Thrombocythemia, Essential × NIS-793 × Clear all
NCT04283526 2021-03-04

Study of Select Combinations in Adults With Myelofibrosis

Novartis

Phase 1 Withdrawn
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡